Wall Street brokerages forecast that Medidata Solutions, Inc. (NASDAQ:MDSO) will post earnings per share (EPS) of $0.31 for the current quarter, according to Zacks. Five analysts have provided estimates for Medidata Solutions’ earnings. The lowest EPS estimate is $0.25 and the highest is $0.38. Medidata Solutions posted earnings of $0.33 per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 6.1%. The firm is expected to issue its next quarterly earnings results on Thursday, February 8th.

On average, analysts expect that Medidata Solutions will report full-year earnings of $1.27 per share for the current year, with EPS estimates ranging from $1.21 to $1.34. For the next financial year, analysts expect that the business will post earnings of $1.46 per share, with EPS estimates ranging from $1.31 to $1.61. Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Medidata Solutions.

Medidata Solutions (NASDAQ:MDSO) last issued its earnings results on Thursday, October 26th. The company reported $0.33 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.02. Medidata Solutions had a net margin of 7.84% and a return on equity of 11.54%. The company had revenue of $140.08 million during the quarter, compared to analysts’ expectations of $141.27 million. During the same period last year, the company posted $0.28 earnings per share. The firm’s quarterly revenue was up 16.7% compared to the same quarter last year.

A number of research analysts have issued reports on MDSO shares. Jefferies Group reaffirmed a “hold” rating and issued a $78.00 target price on shares of Medidata Solutions in a report on Tuesday, August 22nd. KeyCorp reaffirmed a “buy” rating and issued a $86.00 target price on shares of Medidata Solutions in a report on Sunday, September 17th. Royal Bank Of Canada started coverage on shares of Medidata Solutions in a report on Tuesday, September 19th. They issued a “sector perform” rating and a $82.00 target price for the company. Zacks Investment Research raised shares of Medidata Solutions from a “sell” rating to a “hold” rating in a report on Wednesday, September 20th. Finally, Wells Fargo & Company dropped their target price on shares of Medidata Solutions from $83.00 to $80.00 and set a “market perform” rating for the company in a report on Friday, October 27th. Four investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $83.54.

Shares of Medidata Solutions (NASDAQ:MDSO) traded up $0.71 during trading on Thursday, reaching $67.35. 592,072 shares of the company’s stock were exchanged, compared to its average volume of 640,291. Medidata Solutions has a 12 month low of $47.77 and a 12 month high of $85.92. The company has a debt-to-equity ratio of 0.61, a quick ratio of 3.37 and a current ratio of 1.29. The stock has a market capitalization of $3,937.35, a PE ratio of 81.14, a PEG ratio of 4.19 and a beta of 1.71.

In related news, EVP Michael I. Otner sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $70.88, for a total transaction of $708,800.00. Following the sale, the executive vice president now owns 80,674 shares in the company, valued at $5,718,173.12. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Tarek Sherif sold 200,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $68.76, for a total transaction of $13,752,000.00. The disclosure for this sale can be found here. Insiders sold 225,944 shares of company stock worth $15,568,274 over the last quarter. Company insiders own 5.80% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Canada Pension Plan Investment Board raised its stake in Medidata Solutions by 2,994.6% during the third quarter. Canada Pension Plan Investment Board now owns 1,151,200 shares of the company’s stock worth $89,863,000 after purchasing an additional 1,114,000 shares during the period. American Century Companies Inc. raised its stake in Medidata Solutions by 610.9% during the third quarter. American Century Companies Inc. now owns 1,186,843 shares of the company’s stock worth $92,645,000 after purchasing an additional 1,019,883 shares during the period. Eagle Asset Management Inc. raised its stake in Medidata Solutions by 292.9% during the third quarter. Eagle Asset Management Inc. now owns 835,286 shares of the company’s stock worth $66,371,000 after purchasing an additional 622,694 shares during the period. State Street Corp raised its stake in Medidata Solutions by 27.7% during the second quarter. State Street Corp now owns 1,828,913 shares of the company’s stock worth $143,022,000 after purchasing an additional 396,793 shares during the period. Finally, Voya Investment Management LLC raised its stake in Medidata Solutions by 1,571.0% during the second quarter. Voya Investment Management LLC now owns 376,259 shares of the company’s stock worth $29,423,000 after purchasing an additional 353,742 shares during the period. Hedge funds and other institutional investors own 97.52% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “$0.31 Earnings Per Share Expected for Medidata Solutions, Inc. (MDSO) This Quarter” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/03/0-31-earnings-per-share-expected-for-medidata-solutions-inc-mdso-this-quarter.html.

Medidata Solutions Company Profile

Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.

Get a free copy of the Zacks research report on Medidata Solutions (MDSO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Medidata Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc. and related stocks with our FREE daily email newsletter.